-+ 0.00%
-+ 0.00%
-+ 0.00%

“Retreat” after nine months of submission: Emerging ophthalmology Therapist EIR Biopharma withdraws $17 million US stock IPO plan

Zhitongcaijing·11/17/2026 07:01:03
Listen to the news

The Zhitong Finance App learned that EIR Biopharma is a pre-clinical biotechnology company dedicated to developing therapies for ophthalmic diseases introduced through authorization. The company withdrew its IPO plan on Monday. It submitted an application in February 2026 to sell 3.8 million shares at a price of 4 to 5 US dollars each, raising 17 million US dollars.

The San Francisco, California-based company was founded in 2022. It was originally planned to be listed on the NYSE American Board (NYSE American), but the stock code has not yet been selected. Kingswood Capital Markets was originally the sole bookkeeper for the deal.